These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 630331)

  • 1. Magnesium-saving property of an aldosterone antagonist in the treatment of oedema of liver cirrhosis.
    Lim P; Jacob E
    Br Med J; 1978 Mar; 1(6115):755-6. PubMed ID: 630331
    [No Abstract]   [Full Text] [Related]  

  • 2. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
    Dupont A
    Lancet; 1985 Sep; 2(8457):731. PubMed ID: 2863716
    [No Abstract]   [Full Text] [Related]  

  • 3. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of the aldosterone antagonist, canrenoate potassium for treating chronic circulatory insufficiency].
    Sidorenko BA; Kudisov IuM; Rossel's AN; Razumova ET
    Kardiologiia; 1979 Mar; 19(3):41-6. PubMed ID: 372667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of female acne vulgaris with a cream containing the antiandrogen canrenone.
    Nielsen PG
    Dermatologica; 1983; 166(5):275-6. PubMed ID: 6223846
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
    Coltorti M; Radaeli E; Ciaccio S; Corsini R; Trebbi R
    Clin Ter; 1976 Feb; 76(3):215-34. PubMed ID: 963962
    [No Abstract]   [Full Text] [Related]  

  • 7. Lymphocyte function tests in cirrhotic patients under treatment with spironolactone and potassium canrenoate.
    Cuppone R; Del Vecchio S; Zanninelli G; Delle Monache M; Ulissi A; Tavanti A; Angeloni A; Ricci GL
    J Int Med Res; 1988; 16(6):436-42. PubMed ID: 3266156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Indication and experience with an intravenously administered aldosterone-antagonist (soldactone) (author's transl)].
    Kirsch R
    Schweiz Rundsch Med Prax; 1975 Nov; 64(44):1414-7. PubMed ID: 1236699
    [No Abstract]   [Full Text] [Related]  

  • 9. A study of potassium canrenoate on the raised intracranial pressure.
    Node Y; Yajima K; Nakazawa S
    Nihon Ika Daigaku Zasshi; 1984 Apr; 51(2):264-5. PubMed ID: 6736215
    [No Abstract]   [Full Text] [Related]  

  • 10. Gynaecomastia after spironolactone and potassium canrenoate.
    Bellati G; Idéo G
    Lancet; 1986 Mar; 1(8481):626. PubMed ID: 2869341
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of diuretics in preventing ascites recurrence.
    Arrigoni A; Andriulli A; Gindro T; Verme G
    Br J Clin Pract; 1988 Mar; 42(3):116-20. PubMed ID: 3207572
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experience in the treatment of water-salt retentions in cirrhosis by the antialdosterone 11614 R.P].
    Boivin P; Fauvert R
    Rev Int Hepatol; 1969; 19(4):241-51. PubMed ID: 5404532
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of the edemato-ascitic syndrome with an injectable aldosterone antagonist: 8109 CB].
    Dubarry JJ; Bancons J; Quinton A
    Bord Med; 1971 Dec; 4(12):3751-7. PubMed ID: 5146181
    [No Abstract]   [Full Text] [Related]  

  • 14. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of canrenoate potassium given orally in ascitogenic cirrhosis].
    Sarti F; Milandri GL; Piemontese A; Macchia S; Simoni S; Dal Monte PR
    Minerva Dietol Gastroenterol; 1984; 30(3):273-80. PubMed ID: 6504377
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral mannitol in treatment of intractable oedema.
    Misra NP; Ali BN
    J Assoc Physicians India; 1973 Feb; 21(2):229-34. PubMed ID: 4792794
    [No Abstract]   [Full Text] [Related]  

  • 17. [False values of blood digoxin in patients with acute and chronic liver disease. Role of canrenoate potassium and comparison of radioimmunologic and immunoenzymatic methods].
    Nardoni A; di Piazza V; Moretti V; Copetti R; Trinco G; Geatti O
    Clin Ter; 1988 May; 125(4):287-90. PubMed ID: 2974364
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship of bone and plasma magnesium in magnesium-deficient cirrhosis patients.
    Cohen L; Kitzes R
    Isr J Med Sci; 1982 Jun; 18(6):679-82. PubMed ID: 7107204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Triamterene in the depletive treatment of cirrhosis].
    Ravenni G; Rubegni M; Forconi S
    Boll Soc Ital Biol Sper; 1964 Apr; 40(7):290-3. PubMed ID: 5875781
    [No Abstract]   [Full Text] [Related]  

  • 20. [Brain edema in neurosurgery. Trial with an aldosterone-antagonist (soldactone) (author's transl)].
    Anderes JP; de Tribolet N; Zander E
    Schweiz Rundsch Med Prax; 1977 Aug; 66(32):1020-6. PubMed ID: 556440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.